ANIP
Price
$77.68
Change
-$1.47 (-1.86%)
Updated
Jul 22, 02:03 PM (EDT)
Capitalization
1.8B
21 days until earnings call
Intraday BUY SELL Signals
XERS
Price
$8.54
Change
-$0.25 (-2.85%)
Updated
Jul 22, 02:33 PM (EDT)
Capitalization
1.52B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIP vs XERS

ANIP vs XERS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANIP vs. XERS commentary
Jul 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and XERS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2026
Stock price -- (ANIP: $79.15 vs. XERS: $8.78)
Brand notoriety: ANIP and XERS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIP: 37% vs. XERS: 38%
Market capitalization -- ANIP: $1.8B vs. XERS: $1.52B
ANIP [@Pharmaceuticals: Generic] is valued at $1.8B. XERS’s [@Pharmaceuticals: Generic] market capitalization is $1.52B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 1 green FA rating(s).

  • ANIP’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 1 green, 4 red.
According to our system of comparison, XERS is a better buy in the long-term than ANIP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 3 TA indicator(s) are bullish while XERS’s TA Score has 3 bullish TA indicator(s).

  • ANIP’s TA Score: 3 bullish, 6 bearish.
  • XERS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both ANIP and XERS are a bad buy in the short-term.

Price Growth

ANIP (@Pharmaceuticals: Generic) experienced а -1.74% price change this week, while XERS (@Pharmaceuticals: Generic) price change was +6.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +14.56%. For the same industry, the average monthly price growth was +11.12%, and the average quarterly price growth was +19.65%.

Reported Earning Dates

ANIP is expected to report earnings on Aug 12, 2026.

XERS is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+14.56% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($1.8B) has a higher market cap than XERS($1.52B). XERS has higher P/E ratio than ANIP: XERS (125.43) vs ANIP (20.24). XERS YTD gains are higher at: 11.847 vs. ANIP (0.266). ANIP has higher annual earnings (EBITDA): 224M vs. XERS (53.4M). ANIP has more cash in the bank: 326M vs. XERS (112M). XERS has less debt than ANIP: XERS (259M) vs ANIP (614M). ANIP has higher revenues than XERS: ANIP (924M) vs XERS (315M).
ANIPXERSANIP / XERS
Capitalization1.8B1.52B119%
EBITDA224M53.4M419%
Gain YTD0.26611.8472%
P/E Ratio20.24125.4316%
Revenue924M315M293%
Total Cash326M112M291%
Total Debt614M259M237%
FUNDAMENTALS RATINGS
ANIP vs XERS: Fundamental Ratings
ANIP
XERS
OUTLOOK RATING
1..100
7090
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
3848
SMR RATING
1..100
51100
PRICE GROWTH RATING
1..100
5737
P/E GROWTH RATING
1..100
9725
SEASONALITY SCORE
1..100
8543

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XERS's Valuation (87) in the Pharmaceuticals Major industry is in the same range as ANIP (91) in the Pharmaceuticals Other industry. This means that XERS’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is in the same range as XERS (48) in the Pharmaceuticals Major industry. This means that ANIP’s stock grew similarly to XERS’s over the last 12 months.

ANIP's SMR Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for XERS (100) in the Pharmaceuticals Major industry. This means that ANIP’s stock grew somewhat faster than XERS’s over the last 12 months.

XERS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as ANIP (57) in the Pharmaceuticals Other industry. This means that XERS’s stock grew similarly to ANIP’s over the last 12 months.

XERS's P/E Growth Rating (25) in the Pharmaceuticals Major industry is significantly better than the same rating for ANIP (97) in the Pharmaceuticals Other industry. This means that XERS’s stock grew significantly faster than ANIP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPXERS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 10 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ANIP
Daily Signal:
Gain/Loss:
XERS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HUMN30.861.29
+4.36%
Roundhill Humanoid Robotics ETF
ESSC31.070.33
+1.09%
Eventide Small Cap ETF
PEZ100.88N/A
N/A
Invesco DW Consumer Cyclicals Momt ETF
AMDL74.53N/A
N/A
GraniteShares 2x Long AMD Daily ETF
IG20.30-0.04
-0.20%
Principal Investment Grade Corporate ETF

ANIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIP
1D Price
Change %
ANIP100%
+1.84%
AMPH - ANIP
41%
Loosely correlated
-0.20%
COLL - ANIP
40%
Loosely correlated
+0.87%
AMRX - ANIP
36%
Loosely correlated
+3.43%
SNDL - ANIP
31%
Poorly correlated
+0.78%
XERS - ANIP
29%
Poorly correlated
+2.09%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
+2.09%
MIRM - XERS
45%
Loosely correlated
+0.37%
AKBA - XERS
39%
Loosely correlated
+1.56%
KROS - XERS
38%
Loosely correlated
-0.38%
AXON - XERS
37%
Loosely correlated
-3.09%
REPL - XERS
36%
Loosely correlated
+4.66%
More